Overview

This trial is active, not recruiting.

Condition gastric cancer
Sponsor Samsung Medical Center
Start date March 2010
End date March 2013
Trial size 200 participants
Trial identifier NCT01299688, 2009-12-008

Summary

The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
To survey the frequency of HER2(+) CTC in gastric cancer
time frame: 24month

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients older than 18 years ② Patients with localized, histologically confirmed gastric cancer ③ Informed consent form Exclusion Criteria: - No informed consent form

Additional Information

Official title HER2 Circulating Tumor Cells in Gastric Cancer
Principal investigator Won Ki Kang, MD
Description We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.
Trial information was received from ClinicalTrials.gov and was last updated in June 2013.
Information provided to ClinicalTrials.gov by Samsung Medical Center.